Navigation Links
New Drug Application Submitted for Investigational Antibiotic Doripenem

RARITAN, N.J., Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for doripenem, an investigational carbapenem antibiotic for the treatment of nosocomial pneumonia, a pneumonia that is acquired in a hospital or other healthcare setting.

According to the Centers for Disease Control and Prevention (CDC), two million Americans develop hospital-acquired infections each year, and approximately 90,000 die as a result. Approximately 70 percent of these infections are resistant to at least one antibiotic. Pneumonia is the second, most-common, hospital-acquired infection in the United States and is associated with substantial morbidity and mortality.

Doripenem belongs to a class of antibacterial agents called carbapenems, which are useful in treating life-threatening infections caused by Gram-negative(1) and Gram-positive(2) bacteria. The data supporting the NDA showed doripenem was an effective treatment for hospital-acquired pneumonia. The data also demonstrated the effectiveness of doripenem against infections caused by Gram-negative bacteria, such as Pseudomonas aeruginosa and Enterobacteriaceae, including strains of these bacteria that are resistant to other therapies.

Pseudomonas aeruginosa is one of the leading causes of hospital-acquired infections and, because of increasing multi-drug resistance, treatment options are limited. In general, there are few antibiotics available or currently in development to treat the resistant infections - which can be potentially life-threatening - associated with these Gram-negative bacteria.

In clinical trials, doripenem was well-tolerated. The most common treatment-emergent adverse events seen were diarrhea, nausea, constipation, urinary tract infection and decubitus ulcer, commonly known as a bedsore.


'"/>




Page: 1

Related medicine news :

1. Prostate Cancer Can Be Treated By Application Of LASER Technology
2. Varied Applications of Adult Stem Cells to Treat Host of Disorders in Human
3. Venus Remedies Files 5th International Patent Application
4. Roche puts in an Application to Use Herceptin for Treatment in Her-2 positive breast cancer
5. Recd Number of Abstracts Submitted for Sci Cong on Osteoporosis
6. Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke
7. Astrazenecas Investigational Cancer Therapies Revealed at ASCO
8. Antibiotics Dangerous for Diarrhoea in Children Caused by E.Coli
9. Antibiotics Helps Autism
10. Antibiotics losing their power against acne
11. Antibiotic induces liver damage in children with E.COLI infections.
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... the latest in wound care advancements to physician colleagues, skilled nursing facility medical ... titled, "Navigating the Treacherous Waters of Wound Care." , "At many of these ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at http://www.rebound-solution.com/ ...
Breaking Medicine Technology: